Ketabon

Ketabon is a joint venture between HMNC Brain Health and Develco Pharma. The company has developed an oral sustained-release formulation of ketamine for the treatment of treatment-resistant depression (TRD) with minimal side effects. Compared to currently applied intravenous and intranasal ketamine therapies, this sustained-release formulation can minimize dissociative side effects due to its unique pharmacokinetic profile, significantly improving the risk profile and patient convenience. TRD patients who respond inadequately to standard antidepressants account for 30% of the total 320 million people with major depressive disorder globally. Within this group, sustained-release ketamine has demonstrated high response rates.